World Journal of Advanced Research and Reviews
eISSN: 2581-9615 CODEN (USA): WJARAI
Cross Ref DOI: 10.30574/wjarr
Journal homepage: https://wjarr.com/

(REVIEW ARTICLE)

Check for updates

Gliosarcoma: Unraveling the Enigmatic Brain Tumor

Ananya Nayak *

3rd year BBA student(finance), Sri Sri University, Cuttack, Odisha, India.

World Journal of Advanced Research and Reviews, 2023, 19(03), 876–878

Publication history: Received on 01 August 2023; revised on 13 September 2023; accepted on 15 September 2023

Article DOI: https://doi.org/10.30574/wjarr.2023.19.3.1873

Abstract

Gliosarcoma is a rare and aggressive brain tumor characterized by the coexistence of glioblastoma and sarcoma-like elements within the central nervous system. This malignant neoplasm presents unique challenges in diagnosis and treatment due to its complex histological features and aggressive behavior. This article provides an overview of gliosarcoma, including its histological characteristics, clinical presentation, diagnostic methods, treatment options, and ongoing research efforts to improve patient outcomes. Despite its poor prognosis, advances in targeted therapies and multidisciplinary approaches offer hope for enhancing the management of this challenging disease.

Keywords: Gliosarcoma; Brain Tumor; Central Nervous System; Glioblastoma; Sarcoma; Histological Characteristics; Diagnosis; Treatment; Prognosis; Multidisciplinary Approach; Targeted Therapies; Clinical Trials; Aggressive Neoplasm; Molecular Pathways; Patient Outcomes

1. Introduction

Gliosarcoma is a rare and aggressive form of brain cancer that affects the central nervous system. This malignant tumor is characterized by its complex composition, comprising both glioblastoma and sarcoma-like elements, which makes it distinct from other brain tumors. In this article, we will delve into the intricacies of gliosarcoma, exploring its characteristics, diagnosis, treatment options, and the ongoing research aimed at better understanding and managing this challenging disease.

2. Understanding Gliosarcoma

Gliosarcoma, also known as glioblastoma with sarcomatous differentiation, is a subtype of glioblastoma multiforme (GBM), which is one of the most aggressive forms of primary brain tumors. GBM typically arises from glial cells in the brain, such as astrocytes or oligodendrocytes, and accounts for the majority of primary malignant brain tumors in adults. Gliosarcoma, however, presents an unusual twist by incorporating sarcoma-like cells, often resembling connective tissue cells.

3. Characteristics of Gliosarcoma

3.1. Histological Features

Gliosarcoma is defined by its unique histological characteristics. Under the microscope, it exhibits both glial and mesenchymal features. The glial component resembles GBM, with astrocytic cells, while the sarcomatous component comprises spindle-shaped cells, akin to connective tissue.

* Corresponding author: Ananya Nayak

3.2. Aggressiveness

Gliosarcoma is notorious for its aggressive nature. It tends to grow rapidly, invading surrounding brain tissue, which makes complete surgical removal a significant challenge.

3.3. Location

These tumors are commonly found in the cerebral hemispheres of the brain, but they can occur in other regions as well.

3.4. Symptoms

Patients with gliosarcoma may experience symptoms such as headaches, seizures, cognitive impairment, and neurological deficits, depending on the tumor's location and size.

3.5. Diagnosis and Staging

Diagnosing gliosarcoma typically involves a combination of medical imaging (MRI or CT scans) and a biopsy to examine tissue samples under a microscope. Staging is essential to determine the extent of tumor spread and guide treatment decisions. The World Health Organization (WHO) classifies gliosarcoma as a grade IV tumor, which signifies its high malignancy.

3.6. Treatment Options

Treatment for gliosarcoma is multifaceted and often requires a multidisciplinary approach. The following are common treatment modalities:

3.6.1. Surgery

Whenever possible, surgical resection is the primary treatment to remove as much of the tumor as safely achievable. However, due to the infiltrative nature of gliosarcoma, complete removal is often challenging.

3.6.2. Radiation Therapy

Following surgery, radiation therapy is almost always recommended to target any remaining cancer cells. It helps delay tumor recurrence.

3.6.3. Chemotherapy

Chemotherapy, especially temozolomide, is often used in combination with radiation to enhance treatment effectiveness. Newer therapies and clinical trials may also be considered.

3.6.4. Targeted Therapies

Emerging research is exploring targeted therapies that focus on specific molecular pathways within the tumor cells. These therapies aim to inhibit tumor growth and may be used in conjunction with conventional treatments.

3.6.5. Clinical Trials

Participation in clinical trials can offer patients access to cutting-edge treatments and therapies under investigation.

4. Prognosis and Ongoing Research

Gliosarcoma carries a poor prognosis, with a median survival rate of around one year. The aggressive nature of the tumor and the difficulty in achieving complete surgical resection contribute to this challenging outlook. However, ongoing research is exploring new treatment strategies and therapeutic targets that may improve outcomes for patients with gliosarcoma. Early diagnosis and a comprehensive treatment plan remain crucial in the fight against this formidable brain tumor.

5. Conclusion

Gliosarcoma is a rare and aggressive brain tumor that poses significant challenges to both patients and healthcare professionals. While its prognosis remains grim, ongoing research holds promise for improved treatment options and outcomes. A better understanding of the molecular underpinnings of gliosarcoma and the development of targeted

therapies may offer hope for those affected by this enigmatic disease. In the meantime, early detection and a multidisciplinary approach to treatment remain critical in the battle against gliosarcoma.

Compliance with ethical standards

Statement of ethical approval

The present research work does not contain any studies performed on animals or humans.

Reference

[1] Pearson, J. R. D. & Regad, T. Targeting cellular pathways in glioblastoma multiforme. Signal Transduct. Target Ther. 2, 17040. (2017).

[2] Touat, M., Idbaih, A., Sanson, M. & Ligon, K. L. Glioblastoma targeted therapy: Updated approaches from recent biological insights. Ann. Oncol. 28, 1457–1472. (2017).

[3] Saadeh, F., El Iskandarani, S., Najjar, M. & Assi, H. I. Prognosis and management of gliosarcoma patients: A review of literature. Clin. Neurol. Neurosurg. 182, 98–103. (2019).

[4] Lee, D. et al. Clinicopathologic and genomic features of gliosarcomas. J. Neurooncol. 107, 643–650. (2012).

[5] Han, S. J., Yang, I., Tihan, T., Prados, M. D. & Parsa, A. T. Primary gliosarcoma: Key clinical and pathologic distinctions from glioblastoma with implications as a unique oncologic entity. J. Neurooncol. 96, 313–320 (2010).

[6] Woo, P. Y. M. et al. Regression of BRAF (V600E) mutant adult glioblastoma after primary combined BRAF-MEK inhibitor targeted therapy: A report of two cases. Oncotarget 10, 3818–3826 (2019).

[7] Robinson, G. W., Orr, B. A. & Gajjar, A. Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy. BMC Cancer 14, 258. (2014).

[8] Kaley, T. et al. BRAF inhibition in BRAF(V600)-mutant gliomas: Results from the VE-BASKET study. J. Clin. Oncol. 36, 3477–3484. (2018).

[9] Nobre, L. et al. Outcomes of BRAF V600E pediatric gliomas treated with targeted BRAF inhibition. JCO Precis. Oncol. (2020).

[10] Wen, P. et al. RARE-09. Efficacy and safety of dabrafenib + trametinib in patients with recurrent/refractory BRAF V600E–mutated high-grade glioMA (HGG). Neuro Oncol. 20, vi238–vi238 (2018).

[11] Lowder, L. et al. Gliosarcoma: Distinct molecular pathways and genomic alterations identified by DNA copy number/SNP microarray analysis. J. Neurooncol. (2019).

[12] Reis, R. M., Konu-Lebleblicioglu, D., Lopes, J. M., Kleihues, P. & Ohgaki, H. Genetic profile of gliosarcomas. Am. J. Pathol. 156, 425–432. (2000).

[13] Sigismund, S., Avanzato, D. & Lanzetti, L. Emerging functions of the EGFR in cancer. Mol. Oncol. 12, 3–20. (2018).

[14] O'Rourke, D. M. et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci. Transl. Med. (2017).

[15] Bennett, E. E. et al. The prognostic role of tumor volume in the outcome of patients with single brain metastasis after stereotactic radiosurgery. World Neurosurg. 104, 229–238. (2017).